The diabetes market appears poised to post accelerating growth over the coming years.

He has very successfully tackled a niche in the market and appears to have done well so far.

Bristol-Myers' dividend has been an important attraction for value minded investors -- providing the key back-stop for shares even amidst the company's near-term negative growth outlook and lackluster pipeline news.

With Pfizer's diversified product portfolio and cash position that can be used for future deals, we would expect the company to be able to absorb the financial impact.

With Pfizer's diversified product portfolio and cash position that can be used for future deals, we would expect the company to be able to absorb the financial impact,

We are now at an inflection point where I think growth is going to start accelerating.